Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., filed a Form 4 on November 12, 2026, reporting the sale of 250,000 ordinary shares on November 10, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Shares sold: 250,000 ordinary shares disposed of on November 10, 2026
- Weighted average price: $42.2367 per share, with individual transactions ranging from $41.755 to $42.69, inclusive
- Remaining holdings: 927,529 ordinary shares held directly following the reported transaction
- 10b5-1 plan: The sale was executed under a Rule 10b5-1 trading plan adopted by Francis on June 15, 2026
- Reporting person role: Richard D. Francis is identified as President and CEO of Teva Pharmaceutical Industries Ltd.
Details of Richard D. Francis's November 2026 Share Disposal
According to the Form 4 filing, Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), disposed of 250,000 ordinary shares on November 10, 2026. The filing indicates the transaction code was "S," denoting a sale. The reported weighted average price was $42.2367 per share, and the filing notes that the shares were sold in multiple transactions at prices ranging from $41.755 to $42.69, inclusive.
The filing states that the transaction was "effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026." The box on the Form 4 indicating a transaction made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c) is checked. The reporting person undertakes, according to the filing, to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or any security holder.
Following the reported transaction, Francis beneficially owned 927,529 ordinary shares directly, as disclosed in Table I of the filing. No derivative securities transactions were reported in Table II. The Form 4 was signed by Dov Bergwerk as attorney-in-fact for Richard D. Francis and filed on November 12, 2026.
What Was Disclosed
Teva Pharmaceutical Industries Ltd.'s President and CEO, Richard D. Francis, reported the sale of 250,000 ordinary shares on November 10, 2026, at a weighted average price of $42.2367, leaving him with 927,529 directly held shares, all under a pre-established 10b5-1 plan.




Please wait processing your request...